Indications
Treatment of adult and paediatric patients aged 2 years and older with severe or life-threatening manifestations of PIK3CA-related overgrowth spectrum (PROS)
Composition
- Active substance
- alpelisib
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Vijoice
- Active substance
- alpelisib
- ATC code
- L01EM03
- Therapeutic area
- Genetic Diseases, Inborn, Growth Disorders
- Marketing authorisation holder
- Novartis Europharm Limited
- Status
- CHMP opinion
- EMA product number